Article
Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research (abstract OP0015) prese
All News
Richard Conway
Tweet
De Miguel et al. Subclinical GCA in PMR shows different US pattern to classic GCA. Less cranial involvement and more isolated extra-cranial. About what you would have expected given clinical manifestations. @RheumNow #EULAR2022 POS0248 https://t.co/i9IZBdF1vQ
Richard Conway
Tweet
Joanna Robson @Robsonjo4 et al. Disease specific outcome measure for GCA (badly needed!) GCA-PROM. Demonstrated internal and external validity in measuring health related quality of life in GCA patients. @RheumNow #EULAR2022 POS0003 https://t.co/F8pLvlzqD1
Richard Conway
Tweet
Campaniello et al. Ultra-low dose RTX (500/1000mg once a year) vs low dose RTX (500/1000mg 6-monthly) for maintenance in AAV. Comparable relapse free survival 22.7% vs 21.2%, lower severe infection 10.5% vs 26.8% @RheumNow #EULAR2022 POS0837 https://t.co/uBgEmhLUzv
Richard Conway
Tweet
Dr Terrier @TerrierBen Mepolizumab gives clinical benefit in EGPA in terms of remission at week 36/48 and accrued remission. Benefit irrespective of presence of vasculitic features, ANCA status, clinical features, etc @RheumNow #EULAR2022 POS0836 https://t.co/GHwt1WNZEs
Richard Conway
Tweet
Padoan et al. Cancer increased in EGPA. SIR 1.99 (1.22-3.08) all cancer, 1.86 (0.98-2.75) exc. NMSC. Higher ANCA+ 2.42 (1.30-4.16) and CYC treated 2.42 (1.11-4.60). 60% within years 1-5 post diagnosis @RheumNow #EULAR2022 POS0838 https://t.co/9GDLsBknO6
Dr. John Cush
Tweet
Getting Real on PMR
Dr. David Liew talks polymyalgia rheumatica and how our understanding has evolved over the years. #EULAR2022
https://t.co/BCdOTzeOHx https://t.co/VO95uHaKxg
David Liew
Tweet
Do different therapies affect GCA PET scores differently?
n=47 LV-GCA pts, Padua, serial PET
(similar to prev @KQuinnRheum @petercgrayson work)
Need more protocolised data
but can't help but feel steroids alone doesn't quite touch the sides for GCA
POS0813 #EULAR2022 @RheumNow https://t.co/Y1sGmpNyDc
David Liew
Tweet
In case there was doubt:
- steroid toxicity is real in GCA
- giving steroid-sparing therapies (TCZ, MTX) early makes a difference
just something to not forget when your next new GCA patient rolls in the door?
POS0805 #EULAR2022 @RheumNow https://t.co/2wGV3M8wZD
Dr. Rachel Tate
Tweet
Older age, HTN, dyslipidemia, CKD, cancer hx, and chronic liver disease co-morbidities increased risk of COVID19 severity. PMR was the only R-IMID identified and RTX tx also increased risk of severe COVID19. #EULAR2022 POS0203 @RheumNow https://t.co/TnhRnlWkX2
David Liew
Tweet
PMR/GCA patients: should you be worried about how well your COVID vaccine worked?
Actually, post-two vaccines, pretty good Ab (&cellular) response, esp if not on MTX/PNL>10
Glad to see our PMR/GCA pts protected
@VasculitisUMCG @SleenYannick @ElisabethBrouw3 #EULAR2022 @RheumNow https://t.co/9vy0W4ojOF
David Liew
Tweet
There's nothing like a good physical examination
Temporal artery exam & ultrasound vs temporal artery biopsy
n=97 consecutive ?GCA pts from Carlo Salvarini's group
Very decent PPV
Those TA exam findings can be hard to find, but they're gold dust.
POS0820 #EULAR2022 @RheumNow https://t.co/X9TzIqQBaB
Richard Conway
Tweet
Dr Patel @NaomiRheumMD et al. Avacopan in AAV at different thresholds toxicity. Minimum clinically important difference for GTI is 10 points. Avacopan assoc lower glucocorticoid toxicity irrespective of threshold used. @RheumNow #EULAR2022 POS0833 https://t.co/8iIIAsMOlI
Richard Conway
Tweet
Unizony et al. GCA outcome on/after tocilizumab. 36.5% relapse after stopping tocilizumab. Generally stopped due to remission, 10% stopped due to adverse event @RheumNow #EULAR2022 POS0267 https://t.co/jlZDTinfCK
Richard Conway
Tweet
Schmitt et al. Pharmacokinetic study of IV tocilizumab in 24 patients with known GCA. Using 6mg/kg or 7mg/kg. Effective on lab measures and no GCA flares. @RheumNow #EULAR2022 POS0268 https://t.co/uhxfGZvYTw
Richard Conway
Tweet
Pan et al. SPI-62 (11beta-hydroxysteroid dehydrogenase inhibitor) minimises steroid side effects in animal studies. Now going on to a clinical trial in PMR. Exciting as steroid adverse events are a huge problem in PMR/GCA @RheumNow #EULAR2022 POS1332 https://t.co/NEoIx971jS
David Liew
Tweet
Visual symptoms in GCA: should we take it on face value?
@cmukhtyar group tertiary rheum/ophthal
n=350 consecutive GCA pts diagnosed (bx/PET)
visual symptoms 29%
ocular signs 13%
Not all symptoms = signs
No doubt not all symptoms of same concern
POS0810 #EULAR2022 @RheumNow https://t.co/TYHylpBhkN
Richard Conway
Tweet
Mestre-Torres et al. Features at GCA diagnosis that predict permanent vision loss. Age>75, jaw claudication, amaurosis fugax increase risk. Systemic symptoms decrease risk @RheumNow #EULAR2022 POS0271 https://t.co/FPC9R1v8S3
David Liew
Tweet
Check out my thoughts on this work on PMR's immunol signature:
video: https://t.co/7aTJMsR9Te
article: https://t.co/PTDHPv7gZC
for @RheumNow's #EULAR2022 coverage
PS just had a quick chat with @jiemy_william, so much exciting stuff to come from @VasculitisUMCG @ElisabethBrouw3! https://t.co/l94F5qAgDI
Dr. John Cush
Tweet
Watch: EULAR 2022 - Day 1 Faculty Recap Pane
Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at #EULAR2022 - Guidelines, Lupus, and more.
https://t.co/OBLt7dOMa3 https://t.co/lHmEOIFIGa
